Azure Biological: It is estimated that products worth 15 million yuan will be sold to related parties in 2026.

Ulula Bio announced that on December 26, 2025, the company held the 22nd meeting of the fifth board of directors to review and approve the proposed regular related party transactions for the year 2026, which do not need to be submitted for shareholder approval. From January to November 2025, the company actually sold products worth 8.0795 million yuan to Beidahuang Baoquanling Agricultural and Animal Husbandry Development Co., Ltd. and its subsidiaries, which is lower than the estimated amount of 15 million yuan due to market conditions. In 2026, the company plans to sell enzymes and other products to them totaling 15 million yuan, accounting for 1.23% of similar businesses. The pricing of the transactions is based on market prices and will not affect the independence of the company.